Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study.

Published in: Journal of Korean medical science (2022)

Regdanvimab was associated with a significantly lower risk of disease aggravation without increasing adverse reactions.

Keyphrases